Literature DB >> 28035591

Comment on: "Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study".

Kirollos S Kamel1, Paul K L Chin2,3, Matthew P Doogue1,4, Murray L Barclay1,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 28035591     DOI： 10.1007/s40262-016-0481-5

Source DB:  PubMed          Journal:  Clin Pharmacokinet        ISSN： 0312-5963            Impact factor:   6.447


× No keyword cloud information.
  9 in total

1.  Risk of bleeding with dabigatran in atrial fibrillation.

Authors:  Inmaculada Hernandez; Seo Hyon Baik; Antonio Piñera; Yuting Zhang
Journal:  JAMA Intern Med       Date:  2015-01       Impact factor: 21.873

Review 2.  Idarucizumab: The Antidote for Reversal of Dabigatran.

Authors:  John W Eikelboom; Daniel J Quinlan; Joanne van Ryn; Jeffrey I Weitz
Journal:  Circulation       Date:  2015-12-22       Impact factor: 29.690

3.  Risk of bleeding with 2 doses of dabigatran compared with warfarin in older and younger patients with atrial fibrillation: an analysis of the randomized evaluation of long-term anticoagulant therapy (RE-LY) trial.

Authors:  John W Eikelboom; Lars Wallentin; Stuart J Connolly; Mike Ezekowitz; Jeff S Healey; Jonas Oldgren; Sean Yang; Marco Alings; Scott Kaatz; Stefan H Hohnloser; Hans-Christoph Diener; Maria Grazia Franzosi; Kurt Huber; Paul Reilly; Jeanne Varrone; Salim Yusuf
Journal:  Circulation       Date:  2011-05-16       Impact factor: 29.690

4.  Reversal by the specific antidote, idarucizumab, of elevated dabigatran exposure in a patient with rectal perforation and paralytic ileus.

Authors:  C Thorborg; E-P Horn; H Mofid; F Langer
Journal:  Br J Anaesth       Date:  2016-09       Impact factor: 9.166

5.  Idarucizumab for dabigatran reversal - Does one dose fit all?

Authors:  Amihai Rottenstreich; Nivin Jahshan; Limor Avraham; Yosef Kalish
Journal:  Thromb Res       Date:  2016-09-13       Impact factor: 3.944

6.  A randomised study in healthy volunteers to investigate the safety, tolerability and pharmacokinetics of idarucizumab, a specific antidote to dabigatran.

Authors:  Stephan Glund; Viktoria Moschetti; Stephen Norris; Joachim Stangier; Michael Schmohl; Joanne van Ryn; Benjamin Lang; Steven Ramael; Paul Reilly
Journal:  Thromb Haemost       Date:  2015-03-19       Impact factor: 5.249

7.  Management of Dabigatran-Associated Bleeding with Two Doses of Idarucizumab Plus Hemodialysis.

Authors:  Kaylee K Marino; Raul A Santiago; Richard B Dew; Nancy Berliner; Jean M Connors; Nathan T Connell; John Kevin Tucker
Journal:  Pharmacotherapy       Date:  2016-09-25       Impact factor: 4.705

8.  Idarucizumab for Dabigatran Reversal.

Authors:  Charles V Pollack; Paul A Reilly; John Eikelboom; Stephan Glund; Peter Verhamme; Richard A Bernstein; Robert Dubiel; Menno V Huisman; Elaine M Hylek; Pieter W Kamphuisen; Jörg Kreuzer; Jerrold H Levy; Frank W Sellke; Joachim Stangier; Thorsten Steiner; Bushi Wang; Chak-Wah Kam; Jeffrey I Weitz
Journal:  N Engl J Med       Date:  2015-06-22       Impact factor: 91.245

9.  Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study.

Authors:  Stephan Glund; Joachim Stangier; Joanne van Ryn; Michael Schmohl; Viktoria Moschetti; Wouter Haazen; Marina De Smet; Dietmar Gansser; Stephen Norris; Benjamin Lang; Paul Reilly; Jörg Kreuzer
Journal:  Clin Pharmacokinet       Date:  2017-01       Impact factor: 6.447
  9 in total
  1 in total

1.  Authors' Reply to Kamel et al.: "Effect of Age and Renal Function on Idarucizumab Pharmacokinetics and Idarucizumab-Mediated Reversal of Dabigatran Anticoagulant Activity in a Randomized, Double-Blind, Crossover Phase Ib Study".

Authors:  Stephan Glund; Paul Reilly; Joanne van Ryn; Joachim Stangier
Journal:  Clin Pharmacokinet       Date:  2017-02       Impact factor: 6.447
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.